Vera Hirsh

McGill University — Canada

Medicine · Health Sciences

62h-index32.8kcitations268works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(202), Lung Cancer Research Studies(86), Lung Cancer Diagnosis and Treatment(55), Colorectal Cancer Treatments and Studies(55), Bone health and treatments(34)

Publications267 total

Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Clinical Lung Cancer·2023· 4 cited
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology·2023· 42 cited
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).
Journal of Clinical Oncology·2021· 31 cited
OA02.04 Randomized Phase Ⅱ Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2021· 7 cited
P79.05 Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2021Open Access
Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness
American Journal of Health-System Pharmacy·2020· 13 citedOpen Access
Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer
Canadian Association of Radiologists Journal·2020· 85 citedOpen Access
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Journal of Thoracic Oncology·2019· 22 citedOpen Access
EP1.14-28 A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology·2019Open Access
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
The Oncologist·2019· 39 citedOpen Access
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Lung Cancer·2019· 35 citedOpen Access
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Lung Cancer·2019· 31 citedOpen Access
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Journal of Cancer Research and Clinical Oncology·2019· 35 citedOpen Access
Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer
Current Oncology·2019· 45 citedOpen Access
Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer
Current Oncology·2019· 71 citedOpen Access
Analyses des risques concurrents de progression systémique ou au niveau du système nerveux central chez des patients avec CBNPC EGFR muté ayant reçu de l’afatinib dans les études LUX-Lung 3, 6 et 7
Revue des Maladies Respiratoires·2018
Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
Current Oncology·2018· 16 citedOpen Access
P3.01-108 Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC
Journal of Thoracic Oncology·2018Open Access
Randomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0 g/dL
Annals of Oncology·2018· 3 citedOpen Access
P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7
Journal of Thoracic Oncology·2018Open Access
page 1 of 14Next →

Frequent Co-authors

Tony Mok(17), James Chih‐Hsin Yang(14), Kenneth J. O’Byrne(11), Lecia V. Sequist(10), Yi‐Long Wu(9), Dan Massey(9), Frances A. Shepherd(8), Nobuyuki Yamamoto(8), Michael Boyer(8), Martin Schüler(8), Victoria Zazulina(6), Mehdi Shahidi(6), Lesley Seymour(5), Sarayut Lucien Geater(5), Shun Lü(5), Joachim von Pawel(5), Giorgio V. Scagliotti(5), Mark A. Socinski(5), Tudor–Eliade Ciuleanu(4), Andrea Bezjak(4)